OpenURL Connection Search

Select item for more details and to access through your institution.

Predictive value of the early response to chemotherapy in high-risk stages II and III Hodgkin's disease.
Published in:
1987
By:
- Levis, Alessandro;
- Vitolo, Umberto;
- Vasino, Maria A. Ciocca;
- Cametti, Giovanni;
- Urgesi, Alessandro;
- Bertini, Marilena;
- Canta, Marco;
- Monetti, Ugo;
- Bosio, Cesare;
- Jayme, Augusto;
- Resegotti, Luigi;
- Levis, A;
- Vitolo, U;
- Ciocca Vasino, M A;
- Cametti, G;
- Urgesi, A;
- Bertini, M;
- Canta, M;
- Monetti, U;
- Bosio, C
Publication type:
journal article
Adenosplenomegaly and prognosis in uncomplicated and complicated chronic lymphocytic leukemia. A study of 362 cases.
Published in:
1984
By:
- Paolino, Walter;
- Infelise, Vittorio;
- Levis, Alessandro;
- Marmont, Filippo;
- Vitolo, Umberto;
- Paolino, Franco;
- Rossi, Mario;
- Jayme, Augusto;
- Remondino, Mario;
- Paolino, W;
- Infelise, V;
- Levis, A;
- Marmont, F;
- Vitolo, U;
- Paolino, F;
- Rossi, M;
- Jayme, A;
- Remondino, M
Publication type:
journal article
Pola‐R‐CHP for frontline therapy in DLBCL: Are we saving money by spending more?
Published in:
British Journal of Haematology, 2023, v. 202, n. 4, p. 731, doi. 10.1111/bjh.18934
By:
- Vitolo, U.;
- Frascione, P. M. M.;
- Bonello, F.
Publication type:
Article
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma.
Published in:
2001
By:
- Ladetto, M;
- Zallio, F;
- Vallet, S;
- Ricca, I;
- Cuttica, A;
- Caracciolo, D;
- Corradini, P;
- Astolfi, M;
- Sametti, S;
- Volpato, F;
- Bondesan, P;
- Vitolo, U;
- Boccadoro, M;
- Pileri, A;
- Gianni, A M;
- Tarella, C
Publication type:
journal article
Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions.
Published in:
1999
By:
- Tarella, C;
- Corradini, P;
- Astolfi, M;
- Bondesan, P;
- Caracciolo, D;
- Cherasco, C;
- Ladetto, M;
- Giaretta, F;
- Ricca, I;
- Vitolo, U;
- Pileri, A;
- Ferrero, D
Publication type:
journal article
Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
Published in:
Annals of Hematology, 2018, v. 97, n. 8, p. 1301, doi. 10.1007/s00277-018-3366-x
By:
- Carella, A. M.;
- Corradini, P.;
- Mussetti, A.;
- Ricardi, U.;
- Vitolo, U.;
- Viviani, S.
Publication type:
Article
Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Published in:
La Radiologia Medica, 2008, v. 113, n. 4, p. 578, doi. 10.1007/s11547-008-0264-7
By:
- Pelosi, E.;
- Pregno, P.;
- Penna, D.;
- Deandreis, D.;
- Chiappella, A.;
- Limerutti, G.;
- Vitolo, U.;
- Mancini, M.;
- Bisi, G.;
- Gallo, E.
Publication type:
Article
Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation.
Published in:
Bone Marrow Transplantation, 2006, v. 37, n. 8, p. 719, doi. 10.1038/sj.bmt.1705298
By:
- Pavone, V.;
- Gaudio, F.;
- Console, G.;
- Vitolo, U.;
- Iacopino, P.;
- Guarini, A.;
- Liso, V.;
- Perrone, T.;
- Liso, A.
Publication type:
Article
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.
Published in:
Blood Cancer Journal, 2019, v. 9, n. 12, p. 1, doi. 10.1038/s41408-019-0265-x
By:
- Broccoli, A.;
- Argnani, L.;
- Botto, B.;
- Corradini, P.;
- Pinto, A.;
- Re, A.;
- Vitolo, U.;
- Fanti, S.;
- Stefoni, V.;
- Zinzani, P. L.
Publication type:
Article
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
Published in:
Leukemia (08876924), 2015, v. 29, n. 2, p. 464, doi. 10.1038/leu.2014.223
By:
- Robinson, S;
- Dreger, P;
- Caballero, D;
- Corradini, P;
- Geisler, C;
- Ghielmini, M;
- Le Gouill, S;
- Kimby, E;
- Rule, S;
- Vitolo, U;
- Dreyling, M;
- Hermine, O
Publication type:
Article
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma.
Published in:
Leukemia (08876924), 2014, v. 28, n. 9, p. 1885, doi. 10.1038/leu.2014.79
By:
- Corradini, P;
- Vitolo, U;
- Rambaldi, A;
- Miceli, R;
- Patriarca, F;
- Gallamini, A;
- Olivieri, A;
- Benedetti, F;
- Todeschini, G;
- Rossi, G;
- Salvi, F;
- Bruno, B;
- Baldini, L;
- Ferreri, A;
- Patti, C;
- Tarella, C;
- Pileri, S;
- Dodero, A
Publication type:
Article
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.
Published in:
Leukemia (08876924), 2009, v. 23, n. 6, p. 1118, doi. 10.1038/leu.2008.398
By:
- Rossi, D.;
- Rasi, S.;
- Franceschetti, S.;
- Capello, D.;
- Castelli, A.;
- De Paoli, L.;
- Ramponi, A.;
- Chiappella, A.;
- Pogliani, E. M.;
- Vitolo, U.;
- Kwee, I.;
- Bertoni, F.;
- Conconi, A.;
- Gaidano, G.
Publication type:
Article
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial.
Published in:
Leukemia (08876924), 2006, v. 20, n. 10, p. 1840, doi. 10.1038/sj.leu.2404346
By:
- Ladetto, M.;
- Vallet, S.;
- Benedetti, F.;
- Vitolo, U.;
- Martelli, M.;
- Callea, V.;
- Patti, C.;
- Coser, P.;
- Perrotti, A.;
- Sorio, M.;
- Boccomini, C.;
- Pulsoni, A.;
- Stelitano, C.;
- Scimè, R.;
- Boccadoro, M.;
- Rosato, R.;
- De Marco, F.;
- Zanni, M.;
- Corradini, P.;
- Tarella, C.
Publication type:
Article
INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: 5‐YEAR RESULTS OF THE IELSG30 TRIAL.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.48_2879
By:
- Conconi, A.;
- Chiappella, A.;
- Orsucci, L.;
- Gaidano, G.;
- Ferreri, Andrés J.M.;
- Balzarotti, M.;
- Tucci, A.;
- Botto, B.;
- Moccia, A.;
- Vanazzi, A.;
- Merli, F.;
- Tani, M.;
- Esposito, F.;
- Bonomini, L.;
- Vitolo, U.;
- Zucca, E.
Publication type:
Article
COPANLISIB IN COMBINATION WITH RITUXIMAB‐BENDAMUSTINE IN PATIENTS WITH RELAPSED‐REFRACTORY DLBCL: A MULTICENTRIC PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMI.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.167_2880
By:
- Novo, M.;
- Castellino, A.;
- Chiappella, A.;
- Ciccone, G.;
- Balzarotti, M.;
- Di Rocco, A.;
- Spina, M.;
- Vitolo, U.
Publication type:
Article
INTEGRATING TUMOR‐ AND MICROENVIRONMENT‐REFLECTING GENES IN A UNIQUE AND ROUTINE‐APPLICABLE ASSAY FOR ACCURATE RISK PREDICTION IN DLBCL.
Published in:
Hematological Oncology, 2019, v. 37, p. 139, doi. 10.1002/hon.98_2629
By:
- Pileri, S.A.;
- Mazzara, S.;
- Derenzini, E.;
- Melle, F.;
- Motta, G.;
- Tabanelli, V.;
- Vitolo, U.;
- Chiappella, A.;
- Fabbri, M.;
- Agostinelli, C.;
- Tarella, C.;
- Rambaldi, A.;
- Guarini, A.;
- Opinto, G.;
- Vegliante, M.C.;
- De Summa, S.;
- Ciavarella, S.
Publication type:
Article
PET‐DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL).
Published in:
Hematological Oncology, 2019, v. 37, p. 253, doi. 10.1002/hon.62_2630
By:
- Balzarotti, M.;
- Ricardi, U.;
- Spina, M.;
- Monagheddu, C.;
- Tucci, A.;
- Cavallo, F.;
- Zanni, M.;
- Arcari, A.;
- Rusconi, C.;
- Sartori, R.;
- Merli, F.;
- Re, F.;
- Vitolo, U.;
- Dessi, D.;
- Melis, L.;
- Gaidano, G.;
- Chiti, A.;
- Deidda, M.;
- Santoro, A.;
- Ciccone, G.
Publication type:
Article
IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 244, doi. 10.1002/hon.54_2630
By:
- Rusconi, C.;
- Tucker, D.;
- Bernard, S.;
- Muzi, C.;
- Crucitti, L.;
- Stefani, P.;
- Cox, M.;
- Gini, G.;
- Re, A.;
- Sciarra, R.;
- Liberati, A.;
- Morello, L.;
- Arcari, A.;
- Mannina, D.;
- Vitagliano, O.;
- Sartori, R.;
- Chiappella, A.;
- Balzarotti, M.;
- Vitolo, U.;
- Thieblemont, C.
Publication type:
Article
ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma.
Published in:
Hematological Oncology, 2019, v. 37, p. 36, doi. 10.1002/hon.5_2629
By:
- Vitolo, U.;
- Witzig, T.E.;
- Gascoyne, R.D.;
- Scott, D.W.;
- Zhang, Q.;
- Jurczak, W.;
- Özcan, M.;
- Hong, X.;
- Zhu, J.;
- Jin, J.;
- Belada, D.;
- Bergua, J.M.;
- Piazza, F.;
- Mócikova, H.;
- Molinari, A.L.;
- Yoon, D.H.;
- Cavallo, F.;
- Tani, M.;
- Izutsu, K.;
- Kato, K.
Publication type:
Article
RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 52, doi. 10.1002/hon.21_2629
By:
- Chauvie, S.;
- Dalmasso, F.;
- Pierce, L.;
- Vitolo, U.;
- Martelli, M.;
- Sehn, L.H.;
- Trněný, M.;
- Nielsen, T.;
- Sahin, D.;
- Lee, C.;
- Mattiello, F.;
- Berchialla, P.;
- Kinahan, P.E.;
- Kostakoglu, L.
Publication type:
Article
BASELINE TOTAL METABOLIC TUMOUR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 50, doi. 10.1002/hon.20_2629
By:
- Trněný, M.;
- Canales Ruiz, I.;
- Martelli, M.;
- Sehn, L.H.;
- Vitolo, U.;
- Brown, H.;
- Nielsen, T.;
- Sellam, G.;
- Kostakoglu, L.
Publication type:
Article
MULTI‐OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) ‐ INTERIM ANALYSIS OF IELSG46 STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 181, doi. 10.1002/hon.138_2629
By:
- Bruscaggin, A.;
- Mollejo, M.;
- Tapia, G.;
- Gomes da Silva, M.;
- Novak, U.;
- Dietrich, S.;
- Ponzoni, M.;
- Rambaldi, A.;
- Corradini, P.;
- Vitolo, U.;
- Merli, M.;
- Tzankov, A.;
- Cogliatti, S.;
- Montalban, C.;
- Marasca, R.;
- Leval, L.;
- Visco, C.;
- Baptista, M.J.;
- Tousseyn, T.;
- Facchetti, F.
Publication type:
Article
FIRST SALVAGE TREATMENT WITH BENDAMUSTINE AND BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA: A PHASE 2 STUDY OF FIL ONLUS.
Published in:
Hematological Oncology, 2019, v. 37, p. 296, doi. 10.1002/hon.105_2630
By:
- Stefoni, V.;
- Broccoli, A.;
- Botto, B.;
- Corradini, P.;
- Pinto, A.;
- Re, A.;
- Vitolo, U.;
- Fanti, S.;
- Argnani, L.;
- Zinzani, P.
Publication type:
Article
INTEGRATING TUMOR‐ AND MICROENVIRONMENT‐REFLECTING GENES IN A UNIQUE AND ROUTINE‐APPLICABLE ASSAY FOR ACCURATE RISK PREDICTION IN DLBCL.
Published in:
Hematological Oncology, 2019, v. 37, p. 139, doi. 10.1002/hon.98_2629
By:
- Pileri, S.A.;
- Mazzara, S.;
- Derenzini, E.;
- Melle, F.;
- Motta, G.;
- Tabanelli, V.;
- Vitolo, U.;
- Chiappella, A.;
- Fabbri, M.;
- Agostinelli, C.;
- Tarella, C.;
- Rambaldi, A.;
- Guarini, A.;
- Opinto, G.;
- Vegliante, M.C.;
- De Summa, S.;
- Ciavarella, S.
Publication type:
Article
PET‐DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL).
Published in:
Hematological Oncology, 2019, v. 37, p. 253, doi. 10.1002/hon.62_2630
By:
- Balzarotti, M.;
- Ricardi, U.;
- Spina, M.;
- Monagheddu, C.;
- Tucci, A.;
- Cavallo, F.;
- Zanni, M.;
- Arcari, A.;
- Rusconi, C.;
- Sartori, R.;
- Merli, F.;
- Re, F.;
- Vitolo, U.;
- Dessi, D.;
- Melis, L.;
- Gaidano, G.;
- Chiti, A.;
- Deidda, M.;
- Santoro, A.;
- Ciccone, G.
Publication type:
Article
IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 244, doi. 10.1002/hon.54_2630
By:
- Rusconi, C.;
- Tucker, D.;
- Bernard, S.;
- Muzi, C.;
- Crucitti, L.;
- Stefani, P.;
- Cox, M.;
- Gini, G.;
- Re, A.;
- Sciarra, R.;
- Liberati, A.;
- Morello, L.;
- Arcari, A.;
- Mannina, D.;
- Vitagliano, O.;
- Sartori, R.;
- Chiappella, A.;
- Balzarotti, M.;
- Vitolo, U.;
- Thieblemont, C.
Publication type:
Article
ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma.
Published in:
Hematological Oncology, 2019, v. 37, p. 36, doi. 10.1002/hon.5_2629
By:
- Vitolo, U.;
- Witzig, T.E.;
- Gascoyne, R.D.;
- Scott, D.W.;
- Zhang, Q.;
- Jurczak, W.;
- Özcan, M.;
- Hong, X.;
- Zhu, J.;
- Jin, J.;
- Belada, D.;
- Bergua, J.M.;
- Piazza, F.;
- Mócikova, H.;
- Molinari, A.L.;
- Yoon, D.H.;
- Cavallo, F.;
- Tani, M.;
- Izutsu, K.;
- Kato, K.
Publication type:
Article
RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 52, doi. 10.1002/hon.21_2629
By:
- Chauvie, S.;
- Dalmasso, F.;
- Pierce, L.;
- Vitolo, U.;
- Martelli, M.;
- Sehn, L.H.;
- Trněný, M.;
- Nielsen, T.;
- Sahin, D.;
- Lee, C.;
- Mattiello, F.;
- Berchialla, P.;
- Kinahan, P.E.;
- Kostakoglu, L.
Publication type:
Article
BASELINE TOTAL METABOLIC TUMOUR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 50, doi. 10.1002/hon.20_2629
By:
- Trněný, M.;
- Canales Ruiz, I.;
- Martelli, M.;
- Sehn, L.H.;
- Vitolo, U.;
- Brown, H.;
- Nielsen, T.;
- Sellam, G.;
- Kostakoglu, L.
Publication type:
Article
MULTI‐OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) ‐ INTERIM ANALYSIS OF IELSG46 STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 181, doi. 10.1002/hon.138_2629
By:
- Bruscaggin, A.;
- Mollejo, M.;
- Tapia, G.;
- Gomes da Silva, M.;
- Novak, U.;
- Dietrich, S.;
- Ponzoni, M.;
- Rambaldi, A.;
- Corradini, P.;
- Vitolo, U.;
- Merli, M.;
- Tzankov, A.;
- Cogliatti, S.;
- Montalban, C.;
- Marasca, R.;
- Leval, L.;
- Visco, C.;
- Baptista, M.J.;
- Tousseyn, T.;
- Facchetti, F.
Publication type:
Article
FIRST SALVAGE TREATMENT WITH BENDAMUSTINE AND BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA: A PHASE 2 STUDY OF FIL ONLUS.
Published in:
Hematological Oncology, 2019, v. 37, p. 296, doi. 10.1002/hon.105_2630
By:
- Stefoni, V.;
- Broccoli, A.;
- Botto, B.;
- Corradini, P.;
- Pinto, A.;
- Re, A.;
- Vitolo, U.;
- Fanti, S.;
- Argnani, L.;
- Zinzani, P.
Publication type:
Article
Retrospective analysis on R-DHAP/OX and ASCT as salvage treatment for relapsed/refractory high-risk follicular lymphoma.
Published in:
Hematological Oncology, 2017, v. 35, p. 364, doi. 10.1002/hon.2439_119
By:
- Ghione, P.;
- Cavallo, F.;
- Visco, C.;
- Chen, Z.;
- Nicolosi, M.;
- Castellino, A.;
- Tisi, M.C.;
- Dogliotti, I.;
- Boccadoro, M.;
- Leonard, J.P.;
- Vitolo, U.;
- Martin, P.
Publication type:
Article
BIODLCL04: THE PROGNOSTIC ROLE OF CELL OF ORIGIN PROFILE, MYC, BCL2, AND TP53 IN UNTREATED POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA.
Published in:
Hematological Oncology, 2017, v. 35, p. 157, doi. 10.1002/hon.2438_12
By:
- Chiappella, A.;
- Agostinelli, C.;
- Martelli, M.;
- Evangelista, A.;
- Fabbri, M.;
- Melle, F.;
- Motta, G.;
- Righi, S.;
- Novero, D.;
- Balzarotti, M.;
- Cabras, M.G.;
- Carella, A.M.;
- Gotti, M.;
- Pavone, V.;
- Tucci, A.;
- Ladetto, M.;
- Gaidano, G.;
- Vitolo, U.;
- Pileri, S.A.
Publication type:
Article
ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R-CHOP VS PLACEBO/R-CHOP IN UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING.
Published in:
Hematological Oncology, 2017, v. 35, p. 419, doi. 10.1002/hon.2440
By:
- Chiappella, A.;
- Witzig, T.E.;
- Vitolo, U.;
- Gascoyne, R.;
- Russo, J.;
- Amoroso, B.;
- Hudak, K.;
- Ogunkanmi, A.;
- Xu, Y.;
- Ruiz, W.;
- Singh, S.;
- Nowakowski, G.S.
Publication type:
Article
CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY.
Published in:
Hematological Oncology, 2017, v. 35, p. 43, doi. 10.1002/hon.2437_25
By:
- Klanova, M.;
- Sehn, L.H.;
- Bence ‐ Bruckler, I.;
- Cavallo, F.;
- Jin, J.;
- Martelli, M.;
- Stewart, D.;
- Vitolo, U.;
- Zaja, F.;
- Zhang, Q.;
- Mattiello, F.;
- Oestergaard, M.Z.;
- Fingerle ‐ Rowson, G.R.;
- Nielsen, T.;
- Trneny, M.
Publication type:
Article
PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY.
Published in:
Hematological Oncology, 2017, v. 35, p. 131, doi. 10.1002/hon.2437_121
By:
- Sehn, L.H.;
- Oestergaard, M.Z.;
- Trněný, M.;
- Bosi, A.;
- Egyed, M.;
- Illes, A.;
- Nakamae, H.;
- Opat, S.;
- Topp, M.;
- Zaja, F.;
- Fingerle ‐ Rowson, G.;
- Lei, G.;
- Nielsen, T.;
- Punnoose, E.A.;
- Rahman, M.;
- Ray, J.;
- Zhang, L.;
- Martelli, M.;
- Vitolo, U.
Publication type:
Article
CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL).
Published in:
Hematological Oncology, 2017, v. 35, p. 38, doi. 10.1002/hon.2437_19
By:
- Rigacci, L.;
- Puccini, B.;
- Zinzani, P.;
- Kovalchuk, S.;
- Broccoli, A.;
- Evangelista, A.;
- Gioia, D.;
- Mannelli, L.;
- Castagnoli, A.;
- Santoro, A.;
- Bonfichi, M.;
- Rossi, G.;
- Anastasia, A.;
- Zaja, F.;
- Vitolo, U.;
- Pavone, V.;
- Pulsoni, A.;
- Gaidano, G.;
- Stelitano, C.;
- Salvi, F.
Publication type:
Article
NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE ( MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION ( TLA) NGS STRATEGY.
Published in:
Hematological Oncology, 2017, v. 35, p. 151, doi. 10.1002/hon.2438_3
By:
- Ferrero, S.;
- Genuardi, E.;
- Klous, P.;
- Drandi, D.;
- Mantoan, B.;
- Monitillo, L.;
- Barbero, D.;
- Yilmaz, M.;
- Cattellino, F.;
- Vasta, M.;
- Cavallo, F.;
- Cortelazzo, S.;
- Vitolo, U.;
- Luminari, S.;
- Federico, M.;
- Boccadoro, M.;
- Splinter, E.;
- Ladetto, M.
Publication type:
Article
Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study.
Published in:
Hematological Oncology, 2017, v. 35, p. 210, doi. 10.1002/hon.2438_75
By:
- Fowler, N.;
- Gopal, A.K.;
- Schuster, S.J.;
- Trotman, J.;
- Hess, G.;
- Hou, J.;
- Yacoub, A.;
- Lill, M.;
- Martin, P.;
- Vitolo, U.;
- Spencer, A.;
- Radford, J.;
- Jurczak, W.;
- Morton, J.;
- Osmanov, D.;
- Caballero, D.;
- Deshpande, S.;
- Vermeulen, J.;
- Damle, R.;
- Schaffer, M.
Publication type:
Article
PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL).
Published in:
Hematological Oncology, 2017, v. 35, p. 421, doi. 10.1002/hon.2440_4
By:
- Tam, C.S.;
- Rule, S.;
- Le Gouill, S.;
- Vitolo, U.;
- Tsao, L.C.;
- Cavazos, N.;
- Beaupre, D.M.;
- Wang, M.L.
Publication type:
Article
PHASE IB STUDY OF CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS (NHL).
Published in:
Hematological Oncology, 2017, v. 35, p. 53, doi. 10.1002/hon.2437_37
By:
- Michot, J.M.;
- Bouabdallah, R.;
- Doorduijn, J.K.;
- Vitolo, U.;
- Chiappella, A.;
- Kersten, M.J.;
- Zinzani, P.L.;
- Sarmiento, R.;
- Mosulen, S.;
- Petrarca, M.;
- Pourdehnad, M.;
- Hege, K.;
- Yang, Z.;
- Nikolova, Z.;
- Ribrag, V.
Publication type:
Article
POD24 AND CR30 ARE PROMISING SURROGATE ENDPOINTS FOR ASSESSING THE OUTCOME OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA ENROLLED IN THE FOLL05 TRIAL BY FIL.
Published in:
Hematological Oncology, 2017, v. 35, p. 228, doi. 10.1002/hon.2438_91
By:
- Luminari, S.;
- Marcheselli, L.;
- Manni, M.;
- Anastasia, A.;
- Vitolo, U.;
- Chiarenza, A.;
- Rigacci, L.;
- Angelucci, E.;
- Fama, A.;
- Pulsoni, A.;
- Rattotti, S.;
- Angrilli, F.;
- Gaidano, G.;
- Stelitano, C.;
- Bertoldero, G.;
- Cascavilla, N.;
- Salvi, F.;
- Ferreri, A.J.;
- Tarantino, V.;
- Bellei, M.
Publication type:
Article
END OF TREATMENT PET-CT PREDICTS PROGRESSION-FREE SURVIVAL IN DLBCL AFTER FIRST-LINE TREATMENT: RESULTS FROM THE PHASE III GOYA STUDY.
Published in:
Hematological Oncology, 2017, v. 35, p. 184, doi. 10.1002/hon.2438_45
By:
- Kostakoglu, L.;
- Martelli, M.;
- Belada, D.;
- Carella, A.M.;
- Chua, N.;
- Gonzalez ‐ Barca, E.;
- Hong, X.;
- Pinto, A.;
- Sehn, L.H.;
- Shi, Y.;
- Tatsumi, Y.;
- Fingerle ‐ Rowson, G.;
- Mattiello, F.;
- Nielsen, T.;
- Sahin, D.;
- Vitolo, U.;
- Trněný, M.
Publication type:
Article
Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: Phase 2 study of the Italian Lymphoma Foundation.
Published in:
2012
By:
- Ferrario A;
- Pulsoni A;
- Olivero B;
- Rossi G;
- Vitolo U;
- Tedeschi A;
- Merli F;
- Rigacci L;
- Stelitano C;
- Goldaniga M;
- Mannina D;
- Musto P;
- Rossi F;
- Gamba E;
- Baldini L
Publication type:
Journal Article
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease.
Published in:
2012
By:
- Tedeschi A;
- Benevolo G;
- Varettoni M;
- Battista ML;
- Zinzani PL;
- Visco C;
- Meneghini V;
- Pioltelli P;
- Sacchi S;
- Ricci F;
- Nichelatti M;
- Zaja F;
- Lazzarino M;
- Vitolo U;
- Morra E
Publication type:
Journal Article
Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
Published in:
2010
By:
- Rigacci L;
- Fabbri A;
- Puccini B;
- Chitarrelli I;
- Chiappella A;
- Vitolo U;
- Levis A;
- Lauria F;
- Bosi A
Publication type:
Journal Article
Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
Published in:
British Journal of Cancer, 2004, v. 90, n. 2, p. 372, doi. 10.1038/sj.bjc.6601460
By:
- Todeschini, G.;
- Secchi, S.;
- Morra, E.;
- Vitolo, U.;
- Orlandi, E.;
- Pasini, F.;
- Gallo, E.;
- Ambrosetti, A.;
- Tecchio, C.;
- Tarella, C.;
- Gabbas, A.;
- Gallamini, A.;
- Gargantini, L.;
- Pizzuti, M.;
- Fioritoni, G.;
- Gottin, L.;
- Rossi, G.;
- Lazzarino, M.;
- Menestrina, F.
Publication type:
Article

Found: 47